Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Divalent cation-transport integral membrane protein MntH (BRAMP) (MRAMP) | 0.0065 | 0.0033 | 0.5 |
Onchocerca volvulus | Protein Malvolio homolog | 0.0105 | 1 | 0.5 |
Schistosoma mansoni | divalent metal transporter DMT1B | 0.0105 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0105 | 1 | 1 |
Trypanosoma brucei | cytochrome P450, putative | 0.0091 | 0.6503 | 0.5 |
Mycobacterium ulcerans | manganese transport protein MntH | 0.0105 | 1 | 1 |
Echinococcus granulosus | divalent metal transporter DMT1B | 0.0105 | 1 | 0.5 |
Plasmodium vivax | metal transporter, putative | 0.0105 | 1 | 0.5 |
Leishmania major | cytochrome p450-like protein | 0.0091 | 0.6503 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0091 | 0.6503 | 0.6503 |
Loa Loa (eye worm) | hypothetical protein | 0.0105 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0091 | 0.6503 | 0.5 |
Schistosoma mansoni | divalent metal transporter DMT1B | 0.0105 | 1 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0091 | 0.6503 | 0.6503 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0091 | 0.6503 | 0.6503 |
Echinococcus multilocularis | divalent metal transporter DMT1B | 0.0105 | 1 | 0.5 |
Plasmodium falciparum | transporter, putative | 0.0105 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0091 | 0.6503 | 0.5 |
Mycobacterium leprae | DIVALENT CATION-TRANSPORT INTEGRAL MEMBRANE PROTEIN MNTH (BRAMP) (MRAMP) | 0.0065 | 0.0033 | 0.5 |
Toxoplasma gondii | divalent metal transporter, putative | 0.0105 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 100 uM | In vitro inhibitory concentration of the compound against dog kidney Na+/K+ ATPase | ChEMBL. | 10882359 |
Inhibition (binding) | = 0 % | Compound at 100 microM was tested in vitro for the inhibition of dog kidney Na+/K+ ATPase | ChEMBL. | 10882359 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.